NTRA Natera, Inc. - Common Stock

NAS · US · Healthcare · Diagnostics & Research · natera.com

417.00USD+1.62%Mkt Cap: 59.15B $P/E: —Today

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence mon…

Industry Peers

Diagnostics & Research

Screen all

TMO

Thermo Fisher Scientific Inc Common Stock

$242.11BUSDP/E 35.5

DHR

Danaher Corporation Common Stock

Agilent Technologies, Inc. Common Stock

$47.30BUSDP/E 33.1

IQV

IQVIA Holdings, Inc. Common Stock

$42.50BUSDP/E 32.2

WAT

Waters Corporation Common Stock

$41.75BUSDP/E 107.4

ILMN

Illumina, Inc. - Common Stock

$41.23BUSDP/E 50.8

IDXX

IDEXX Laboratories, Inc. - Common Stock

$40.89BUSDP/E 36.4

MTD

Mettler-Toledo International, Inc. Common Stock

$29.78BUSDP/E 34.0

DGX

Quest Diagnostics Incorporated Common Stock

$25.75BUSDP/E 25.0

Labcorp Holdings Inc. Common Stock

$25.02BUSDP/E 25.5

Guardant Health, Inc. - Common Stock

$23.86BUSD

RVTY

Revvity, Inc. Common Stock

$16.91BUSDP/E 72.5

MEDP

Medpace Holdings, Inc. - Common Stock

$16.73BUSDP/E 35.2

ERF

Eurofins Scientific SE

$14.05BUSDP/E 26.2

CRL

Charles River Laboratories International, Inc. Common Stock

$13.85BUSD

ICLR

ICON plc - Ordinary Shares

Qiagen N.V. Common Shares

$9.24BUSDP/E 22.7

GRAL

GRAIL, Inc. - Common Stock

$6.40BUSD

Key Statistics

Company

Market Cap59.15B USD

Enterprise Value58.30B USD

Revenue (TTM)2.71B USD

Gross Profit1.49B USD

Net Income (TTM)-208.16M USD

Revenue/Share19.32 USD

Last Price417.00 USD

Fiscal Year EndDec 2025

MR QuarterJun 2026

Employees6.1K

CountryUS

SectorHealthcare

IndustryDiagnostics & Research

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-2989.15

PEG—

EV/EBITDA-259.76

EV/Revenue21.53

P/S21.85

P/B32.35

EPS (TTM)-1.35

EPS (Forward)-0.14

52W Range

157.4396% of range427.47

52W High427.47 USD

52W Low157.43 USD

Profitability

Gross Margin64.75%

Oper. Margin-10.29%

EBITDA Margin-8.29%

Profit Margin-9.03%

ROE-12.16%

ROA-8.68%

Growth

Revenue Growth37.70%

Earnings Growth—

Cash Flow & Leverage

Operating CF215.30M USD

CapEx (TTM)139.19M USD

FCF Margin3.84%

FCF Yield0.18%

Net Debt-853.01M USD

Net Debt/EBITDA3.80

Balance Sheet

Debt/Equity0.13

Current Ratio3.00

Quick Ratio2.74

Book Value/Sh12.68 USD

Cash/Share7.57 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 USD

Div. Yield0.00%

5Y Avg Yield—

Payout Ratio—

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating1.4 (Strong Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)361.16 USD

Upside (mean)-13.4%

Target Range280.00 USD – 475.00 USD

280.00-13.4% to mean475.00

# Analysts22

Ownership

Shares Out.144.14M

Float140.12M

Insiders2.81%

Institutions96.73%

Short Interest

Short Ratio4.1d

Short % Float3.43%

Short % Out.3.33%

Shares Short4.80M

Short (prev mo.)4.30M

Technical

SMA 50331.07 (+26.0%)

SMA 200249.05 (+67.4%)

Beta1.53

S&P 52W Chg14.58%

Avg Vol (30d)1.40M

Avg Vol (10d)1.81M

Technical Indicators

RSI (14)78.9

MACD27.9618

MACD Signal25.7837

MACD Hist.+2.1781

BB Upper444.47 USD

BB Middle369.23 USD

BB Lower293.99 USD

BB Width40.75%

ATR (14)13.33 USD

Vol Ratio (20d)1.26x